1 / 21

New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention

New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention. Prof. Ulf Landmesser University Hospital Zürich Switzerland. New concepts and guidelines in the management of LDL-C and CV Risk: Need for early intervention.

calvin
Download Presentation

New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland

  2. New concepts and guidelines in the management of LDL-C and CV Risk: Need forearlyintervention • Need forimprovement in managmentofcardiovascularrisk • What do currentguidelinespropose ? • Whatneedstobeexploredbeyondcurrentguidelinerecommendations ?

  3. Clinical presentation of coronary disease First clinical presentation of coronary artery disease is frequently an acute coronary syndrome. i.e. can be the last … Men 62 % 46 % Women 0 20 40 60 Patients (%) Framingham Heart Study Murabitoet al Circulation 1993; 88: 2548-54 Courtasy of John Deanfield

  4. Frequency and mortality of a first coronary event 28.9 % 9.5 % 61.6 % • 384,597 Individuals with first coronary event (Coronary death or first acute myocardial infarction – population aged 35-84) Dudas K et al.; Circulation 2011; 123: 46-52

  5. Recommendationsregarding riskestimation European Heart Journal 2012;33:1635–1701

  6. Estimatedriskas a functionofhigh-densitylipoprotein-cholesterol (HDL-C) forwomen in populationsathighcardiovasculardiseaserisk Eur Heart J 2011;32(14):1769-1818 Atherosclerosis 2011;217(1):3-46

  7. SCORE charts with HDL-C For use in low risk regions: HDL-C= 1.8 mmol/L (70 mg/dl) SCORE charts with HDL-C For use in low risk regions: HDL-C= 0.8 mmol/L (32 mg/dl) Eur Heart J 2011;32(14):1769-1818 Atherosclerosis 2011;217(1):3-46

  8. Intervention strategies as a functionof total CV riskand LDL-C level Eur Heart J 2011;32(14):1769-1818 Atherosclerosis 2011;217(1):3-46

  9. Recommendationsforlipidanalysesastreatmenttarget in thepreventionof CVD Eur Heart J 2011;32(14):1769-1818 Atherosclerosis 2011;217(1):3-46

  10. European Guidelines on cardiovascular disease prevention in clinicalpractice (version 2012) Eur Heart J 2012;33:1635-1701

  11. Recommendationsforgenetictesting European Heart Journal 2012;33:1635–1701

  12. Comparisonof different imagingandcirculatingbiomarkersforcardiovascularriskestimation Yeboah J et al.; JAMA. 2012 Aug 22;308(8):788-95 • - Multi-Ethnic Study ofAtherosclerosis (MESA) analysis • FRS >5%-<20%: 1330 intermediate risksubjects (from 6814 subjects), • 7.6 yearsoffollow-up • 6 markers: • coronaryarterycalcium, • carotidintima-mediathickness, • ankle-brachial index, • brachial flow-mediateddilation, • high-sensitivity C-reactiveprotein (CRP), • familyhistoryofcoronaryheartdisease (CHD) • Conclusions: Coronaryarterycalcium, ankle-brachial index, high-sensitivity CRP, andfamilyhistorywereindependentpredictorsofincident CHD/CVD in intermediate-risk individuals. • Coronaryarterycalciumprovidedsuperiordiscriminationandriskreclassificationcomparedwithotherriskmarkers.

  13. Recommendations on managementofhyperlipidaemia European Heart Journal 2012;33:1635–1701

  14. Is there evidence for a benefit of statin therapy in people at low risk of vascular disease ? Interpretation: In individuals with 5-year risk of major vascular events lower than 10%, each 1 mmol/L reduction in LDL cholesterol produced an absolute reduction in major vascular events of about 11 per 1000 over 5 years. This benefit greatly exceeds any known hazards of statin therapy. Under present guidelines, such individuals would not typically be regarded as suitable for LDL-lowering statin therapy. The present report suggests, therefore, that these guidelines might need to be reconsidered. Cholesterol Treatment Trialists' (CTT) Collaborators; Lancet. 2012 Aug 11; 380(9841):581-90

  15. Is there evidence for a benefit of statin therapy in people at low risk of vascular disease ? Cholesterol Treatment Trialists' (CTT) Collaborators; Lancet. 2012 Aug 11; 380(9841):581-90

  16. Major vasculareventsavoided in different cardiovascularriskcohortscategories Cholesterol Treatment Trialists' (CTT) Collaborators; Lancet. 2012 Aug 11; 380(9841):581-90

  17. Recommendationsfortreatmenttargetsfor LDL-C Eur Heart J 2011;32(14):1769-1818 Atherosclerosis 2011;217(1):3-46

  18. JAMA. 2012 Mar 28;307(12):1302-9

  19. Comparison HPS2-THRIVE and Aim-High trial HPS2-THRIVE trial AIM-HIGH trial (N Engl J Med 2011) • Pre-randomisation phase with niacin (1.5/2g) exclusion: 20.1 % • Aiming to have similarly low LDL-C in both treatment groups • LDL: - 5.5 %, HDL: + 13.2 % • More patients on high-dose statin • or ezetimibe in control-group • Randomization (n): 1718 vs. 1696 patients • Mean FU - 3 years (556 events) • Pre-randomisation phase with ER-niacin (2g)/ • laropiprantexclusion: 25.4 % • No further adjustment of LDL-C levels after randomization • LDL: -20 %; HDL + 17 % • Addition of laropiprant • (Antagonist of PGD2receptor DP1) • Randomization (n): 12838 vs. 12835 patients • Mean FU - 4 years (? events) HPS2-THRIVE clinical outcome data (presentation expected in 2013)

  20. Lipid-targeted Therapies What should be added to statins in patients with high vascular risk ? Statin therapy HDL-C Further LDL-C Combined LDL-C HDL-C • Reconstituted HDLs • ApoA1 modulation • NPC1L1 (Ezetimibe*) • PCSK9 inhibition • (Monoclonal Ab*) • ApoB-100 Antisense oligonucleotides • Niacin/Laropiprant* • CETP inhibition • (Anacetrapib*,Evacetrapib*) *Clinical outcometrialsongoing

  21. HDL metabolism – HDL-C canbeincreasedbyseveralmechanisms (2) apoA-I (lipid-free) (3) ABCA-1 expression (4) SR-BI inhibition (1) CETP inhibition Besler C et al. & Landmesser U. EMBO Mol Med 2012; 4(4):251-68

More Related